De Novo Mutations in Ataxin-2 Gene and ALS Risk

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Laffita Mesa, José Miguel ^a,b   Rodríguez Pupo, Jorge Michel ^c   Moreno Sera, Raciel ^g   Vázquez Mojena, Yaimee ^a   Kourí, Vivian ^d   Laguna Salvia, Leonides ^c   Martínez Godales, Michael ^d   Valdevila Figueira, José A ^c   Bauer, Peter O ^f   Rodríguez Labrada, Roberto ^a,b   Zaldívar, Yanetza González ^a   Paucar, Martin ^e   Svenningsson, Per ^e   Pérez, Luís Velázquez ^a,b  

^a Centro para la Investigacion y Rehabilitacion de las Ataxias Hereditarias Cuba   (Cuba)

^b Branch of Biomedicine of the Cuban Academy of Sciences ACC   (Cuba)

^c Clinical and Surgical Hospital Lucía Íñiquez Landín   (Cuba)

^d INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MAYO GRADUATE SCHOOL   (United States)

^g Policlinic and Medical Faculty   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ATAXIN 2; CYTOSINE; GUANINE; NUCLEIC ACID BINDING PROTEIN; POLYGLUTAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATAXIN 2 GENE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HAPLOTYPE; HUMAN; MALE; PATHOGENESIS; RISK ASSESSMENT; TRINUCLEOTIDE REPEAT;

ADULT; AGED; ALLELES; AMYOTROPHIC LATERAL SCLEROSIS; BASE SEQUENCE; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; PEDIGREE; PEPTIDES; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 84881166342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070560     Document Type: Article

References (49)

1. Andersen PM, Al-Chalabi A, (2011) Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol 7: 603-615.
2. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466: 1069-1075.
3. Lee T, Li YR, Ingre C, Weber M, Grehl T, et al. (2011) Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 20: 1697-1700.
4. Corrado L, Mazzini L, Oggioni GD, Luciano B, Godi M, et al. (2011) ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. doi 10.1007/s00439-011-1000-2.
5. Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught P, et al. (2011) Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 76: 2066-2072.
6. Laffita-Mesa JM, Velázquez-Pérez LC, Santos Falcón N, Cruz-Mariño T, González Zaldívar Y, et al. (2012) Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Hum Genet. 2011. doi:10.1038/ejhg.2011.154.
7. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, et al. (2011) The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol. Dis: doi:10.1016/j.nbd.2011.08.021.
8. Futamura N, Matsumura R, Fujimoto Y, Horikawa H, Suzumura A, et al. (1998) CAG repeat expansions in patients with sporadic cerebellar ataxia. Acta Neurol Scand 98: (1), 55-9.
9. Fernandez M, McClain ME, Martinez RA, Snow K, Lipe H, et al. (2000) Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 22, 55(4), 569-72.
10. Costanzi-Porrini S, Tessarolo D, Abbruzzese C, Liguori M, Ashizawa T, et al. (2000) An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 54: 491-493.
11. Santos N, Aguiar J, Fernández J, Vázquez M, Auburger, et al, (1999) Molecular diagnosis of a sample of the Cuban population with spinocerebellar ataxia type 2. BiotecnologiaAplicada 16: 219-221.
12. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14: 269-276.
13. Mao R, Aylsworth AS, Potter N, Wilson WG, Breningstall G, et al. (2002) Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. Am J Med Genet 15: 110(4), 338-45.
14. Paciorkowski A, Shafrir Y, Hrivnak J, Patterson MC, Tennison MB, et al. (2011) Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms Neurology 77, 1055-1060.
15. Lahut S, Omur O, Uyan O, Agi{dotless}m ZS, Ozoguz A, et al. (2012) ATXN2 and Its Neighbouring Gene SH2B3 Are Associated with Increased ALS Risk in the Turkish Population. PLoS ONE 7(8): e42956 doi:10.1371/journal.pone.0042956.
16. Van Langenhove T, van der Zee J, Engelborghs S, Vandenberghe R, Santens P, et al. (2011) Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2011.09.025.
17. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, et al. (2011) Ataxin-2 repeat-length variation and neurodegeneration. Hum MolGenet 20: 3207-3212.
18. Chen Y, Huang R, Yang Y, Chen K, Song W, et al. (2011) Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 32: 1925 e1921-1925.
19. Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, et al. (2011) Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 68: 739-742.
20. Gellera C, Ticozzi N, Pensato V, Nanetti L, Castucci A et al. (2012) ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2012.02.004.
21. Stevanin G, Giunti P, Belal GD, Belal S, Durr A et al. (1998) De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Hum Mol Genet 7: (11), 1809-13.
22. Bauer P, Kraus J, Matoska V, Brouckova M, ZumrovaAet al. (2004). Large de novo expansion of CAG repeats in patient with sporadic spino-cerebellar ataxia type 7. J Neurol 251, 1023-1024.
23. Mittal U, Sanghamitra R, Satish J, Srivastava AK, Mukerji M, et al. (2005) Post-zygotic de novo trinucleotide repeat expansion at spinocerebellar ataxia type 7 locus: evidence from an Indian family J Hum Genet. 50: 155-157.
24. Shizuka M, Watanabe M, Ikeda Y, Mizushima K, Okamoto K, Shoji M, (1998) Molecular analysis of a de novo mutation for spinocerebellar ataxia type 6 and (CAG)n repeat units in normal elder controls. J Neurol Sci 161: 85-87.
25. Almqvist EW, Elterman DS, MacLeod PM, Hayden MR, (2001) High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 60: 198-205.
26. Schöls L, Szymanski S, Peters S, Przuntek H, Epplen JT, et al. (2000) Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 107: 132-137.
27. Alonso E, Martínez-Ruano L, De Biase I, Mader C, Ochoa A, et al. (2007) Distinct distribution of autosomal dominant Spinocerebellar Ataxia in the Mexican population. Movement Disorders 22: 1050-1053.
28. Soraru G, Clementi M, Forzan M, Orsetti V, D'Ascenzo C, et al. (2011) ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 76: 2030-2031.
29. Fischbeck KH, Pulst SM, (2011) Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2. Neurology 76: 2050-2051.
30. Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC, Almaguer-Mederos LE, Cruz-Mariño T, et al. (2011) A Comprehensive Review of Spinocerebellar Ataxia Type 2 in Cuba. Cerebellum10: 184-198.
31. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256.
32. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268.
33. Zaldivar T, Gutiérrez J, Lara G, Carbonara M, Logroscino G, et al. (2009) Reduced frequency of ALS in an ethnically mixed population A population-based mortality study. Neurology 72: 1640-45.
34. Choudhry S, Mukerji M, Srivastava AK, Jain S, (2001) Brahmachari (2001) CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. Hum Mol Genet 10(21): 2437-46.
35. Ramos EM, Martins S, Alonso I, Emmel VE, Saraiva-Pereira ML, et al. (2010) Common origin of pure and interrupted repeat expansions in spinocerebellar ataxia type 2 (SCA2). Am J Med Genet B Neuropsychiatr Genet153B: 524-531.
36. Gispert S, Twells R, Orozco G, Brice A, Weber J, et al. (1993) Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet 4(3), 295-9.
37. Hernandez A, Magarino C, Gispert S, Santos N, Lunkes A, et al. (1995) Genetic mapping of the spinocerebellar ataxia 2 (SCA2) locus on chromosome 12q23-q24.1. Genomics 20 25(2): 433-5.
38. Laffita-Mesa JM, Bauer PO, Kourí V, Peña Serrano L, Roskams J, et al. (2012) Epigenetics DNA-Methylation in the core ataxin-2 gene promoter: Novel physiological and pathological implications. Hum Genet. doi:10.1007/s00439-011-1101-y.
39. Mizushima K, Watanabe M, Kondo I, Okamoto K, Shizuka M, et al. (1999) Analysis of spinocerebellar ataxia type 2 gene and haplotype analysis: (CCG) 1-2 polymorphism and contribution to founder effect. J Med Genet 36: 112-114.
40. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, et al. (2011) PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 6: e17951.
41. Albrecht M, Golatta M, Wullner U, Lengauer T, (2004) Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 271: 3155-70.
42. Hart M, Gitler A (2012) ALS-Associated Ataxin 2 PolyQ Expansions Enhance Stress-Induced Caspase 3 Activation and Increase TDP-43 Pathological Modifications. doi:10.1523/JNEUROSCI.0996-12.2012.
43. Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD (2012) Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol. doi:10.1007/s00401-012-0985-5.
44. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, et al. (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117: 137-149.
45. Brooks BR, Miller RG, Swash M, Munsat TL, (2000) for the World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293-299.
46. Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, et al. (2012) Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 79: 66-72.
47. Lee T, Li YR, Chesi A, Hart MP, Ramos D, et al. (2011) Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 76: 2062-2065.
48. Liu X, Lu M, Tang L, Zhang N, Chui D, et al. (2012) ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiology of Aging.dx.doi.org/10.1016/j.neurobiolaging.2013.04.009.
49. Conforti FL, Spataro R, Sproviero W, Cavalcanti F, Condino F, et al. (2012) Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral Sclerosis. Neurology. doi:10.1212/WNL.0b013e318278b618.